Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Kou, Lianmeng"'
Autor:
Fanta, Biruk Sintayehu, Mekonnen, Laychiluh, Basnet, Sunita K.C., Teo, Theodosia, Lenjisa, Jimma, Khair, Nishat Z., Kou, Lianmeng, Tadesse, Solomon, Sykes, Matthew J., Yu, Mingfeng, Wang, Shudong
Publikováno v:
In Bioorganic & Medicinal Chemistry 15 February 2023 80
Autor:
Long, Yi, Yu, Mingfeng, Ochnik, Aleksandra M., Karanjia, Jasmine D., Basnet, Sunita KC., Kebede, Alemwork A., Kou, Lianmeng, Wang, Shudong
Publikováno v:
In European Journal of Medicinal Chemistry 5 March 2021 213
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Fanta, Biruk Sintayehu, Lenjisa, Jimma, Teo, Theodosia, Kou, Lianmeng, Mekonnen, Laychiluh, Yang, Yuchao, Basnet, Sunita K. C., Hassankhani, Ramin, Sykes, Matthew J., Yu, Mingfeng, Wang, Shudong
Publikováno v:
Molecules; Apr2023, Vol. 28 Issue 7, p2951, 21p
Autor:
Biruk Sintayehu Fanta, Jimma Lenjisa, Theodosia Teo, Lianmeng Kou, Laychiluh Mekonnen, Yuchao Yang, Sunita K. C. Basnet, Ramin Hassankhani, Matthew J. Sykes, Mingfeng Yu, Shudong Wang
Publikováno v:
Molecules; Volume 28; Issue 7; Pages: 2951
Cyclin-dependent kinase 2 (CDK2) has been garnering considerable interest as a target to develop new cancer treatments and to ameliorate resistance to CDK4/6 inhibitors. However, a selective CDK2 inhibitor has yet to be clinically approved. With the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::edc98578287333e44ce81e9ca77f5f01
Autor:
Biruk Sintayehu Fanta, Laychiluh Mekonnen, Sunita K.C. Basnet, Theodosia Teo, Jimma Lenjisa, Nishat Z. Khair, Lianmeng Kou, Solomon Tadesse, Matthew J. Sykes, Mingfeng Yu, Shudong Wang
Publikováno v:
Bioorganic & Medicinal Chemistry. 80:117158
Refereed/Peer-reviewed Deregulation of cyclin-dependent kinase 2 (CDK2) and its activating partners, cyclins A and E, is associated with the pathogenesis of a myriad of human cancers and with resistance to anticancer drugs including CDK4/6 inhibitors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b8f63a551dceced78f485f06da01662
https://doi.org/10.1016/j.bmc.2023.117158
https://doi.org/10.1016/j.bmc.2023.117158
Autor:
Jasmine D. Karanjia, Lianmeng Kou, Alemwork A. Kebede, Yi Long, Sunita K.C. Basnet, Aleksandra M. Ochnik, Mingfeng Yu, Shudong Wang
Feline McDonough sarcoma (FMS)-like tyrosine kinase 3 (FLT3) is one of the most pursued targets in the treatment of acute myeloid leukaemia (AML) as its gene amplification and mutations, particularly internal tandem duplication (ITD), contribute to t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec4d5f6657f1b038a6811349efb468e8
https://hdl.handle.net/11541.2/147361
https://hdl.handle.net/11541.2/147361
